Product Description
Bifeprunox is an atypical antipsychotic drug with mixed (agonist/antagonist) receptor activity with the neurotransmitters dopamine (D2/3/4) and serotonin. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bifeprunox#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: D2 Agonist,5-HT Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Schizophrenia|Psychotic Disorders|Alzheimer Disease|Bipolar Disorder|Body Weight Changes
Phase 2: Psychotic Disorders|Schizophrenia|Bipolar Disorder|Affective Disorders, Psychotic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 11916A | P3 |
Terminated |
Schizophrenia |
2009-08-01 |
|
| 11915A | P3 |
Terminated |
Schizophrenia |
2009-08-01 |
|
| 2007-001097-90 | P3 |
Terminated |
Schizophrenia |
2009-06-19 |
|
| 3168A2-1005 | P1 |
Completed |
Healthy Volunteers |
2008-12-01 |